Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patientsEstudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351

ovartis Farmaceútica S.A0 个研究点目标入组 40 人开始时间: 2005年9月6日最近更新: 2015年2月16日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•a.Male and female patients ? 16 years of age.
•b.Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant.
•c.The graft must be functional within 48 hours post transplantation. A functional graft is defined at the investigator’s determination by a 50 % fall of serum creatinine from the pre-transplant value. In the event of dialysis immediately preceding transplantation, the pre-dialysis serum creatinine value may be used.
•d.Females capable of becoming pregnant must have a negative pregnancy test (qualitative dip stick test on urine) immediately prior to study entry. Females of child bearing potential must practice an approved method of birth control for the one year duration of the study and for a period of three months following discontinuation of study medication.
•e.Patients who are willing and able to participate in the whole course of the study and for whom written informed consent has been obtained from the parent(s) or legal guardian.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•a.Cold ischemia time > 40 hours.
•b.Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs.
•c.Patients with non-diarrhea associated hemolytic-uremic syndrome.
•d.Recipients of donor specific transfusions.
•e.Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.
•f.Patients unable to undergo renal biopsies post-transplant.
•g.Induction therapy with ALG, ATG and OKT3.
•h.Use of anti-fungal azoles such as ketoconazole, itraconazole and fluconazole.
•i.Patients requiring treatments with rifampin, carbamazepine, phenobarbital, phenytoin at the time of entry in the study.
•j.The use of any investigational drug within 4 weeks prior to administration of the initial dose of study medication.
•k.Patients who have received an investigational immunosuppressive agent within 4 months prior to administration of the initial dose of study medication.
•l.Presence of any severe allergy (within 4 weeks prior to administration of the initial dose of study medication) requiring acute or chronic treatment; or hypersensitivity to drugs similar to RAD001 (e.g., erythromycin or other macrolide antibiotics) or to any component of the formulation.
•m.Patients with any known contraindication to CsA.
•n.Patients with severe or unstable medical conditions likely to affect patient safety or the objectives of this study. Other social circumstances that prevent full compliance with the protocol.
•o.Patients with a history of alcohol or drug abuse, or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to cooperate fully with the study.
•p.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:
•presence of inflammatory bowel syndrome, or gastrointestinal bleeding;
•history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection (bladder augmentations and feeding tubes are acceptable).
•q.Patients who are Hepatitis C positive, HIV positive, or Hepatitis B surface antigen positive. Laboratory results obtained within 6 months prior to administration of the initial dose of study medication are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen, Hepatitis C or HIV.
•r.Evidence of liver injury as indicated by abnormal liver tests (AST or ALT > 3 times ULN, total bilirubin > 2 mg/dL).
•s.Presence of uncontrolled hypercholesterolemia ( =350 mg/dL, = 9.1 mmol/L) or hypertriglyceridemia (= 500 mg/dL, = 5.6 mmol/L).
•t.White blood cell count = 4500/mm3 or platelet count = 100,000/mm3.
•u.Patients with severe systemic infections.
•v.Patients with any past or present malignancy (other than excised basal cell carcinoma).
•w.History of splenectomy.
•x.Patients with any history of significant coagulopathy or medical condition requiring long term systemic anticoagulation after transplantation which would interfere with obtaining biopsies. Low dose aspirin is allowed.
•y.Abnormal physical or laboratory findings of clinical significance which would interfere with the objectives of the study.
•z.Females who are breast feeding.

研究者

发起方

ovartis Farmaceútica S.A

相似试验

进行中（未招募）

1 期

EUCTR2018-004449-18-BGPromethera Biosciences24

进行中（未招募）

1 期

EUCTR2018-004449-18-PLPromethera Biosciences24

进行中（未招募）

1 期

EUCTR2018-004449-18-FRPromethera Biosciences24

进行中（未招募）

1 期

HEP201-PANASH is an interventional study of increasing doses of HepaStem for the treatment of patients with cirrhotic and pre-cirrhotic NASH. The population will be administered with single or repeated infusions of the IMP in an ascending manner. The safety and tolerability of HepaStem in the treatment of NASH will be first evaluated as well as preliminary efficacy.

EUCTR2018-004449-18-BEPromethera Biosciences36

进行中（未招募）

1 期

HEP201-PANASH is an interventional study of increasing doses of HepaStem for the treatment of patients with cirrhotic and pre-cirrhotic NASH. The population will be divided in 4 cohorts and a total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner. The safety and tolerability of HepaStem in the treatment of NASH will be first evaluated as well as preliminary efficacy.ASH is characterized by steatosis, inflammation and cytological ballooning with varying amounts of fibrosis. Patients with NASH are at risk of cardiovascular morbidity and mortality. In chronic liver disease, changes in inflammatory components of the liver are not limited to the sole organ, but has a systemic influence. Disease evolution is characterized by increasing fibrosis and cirrhosis in a subset of patients, and a degree of fibrosis linked with increased risk of mortality.MedDRA version: 20.0 Level: SOC Classification code 10019805 Term: Hepatobiliary disorders System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: LLT Classification code 10031743 Term: Other chronic nonalcoholic liver disease System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: PT Classification code 10019708 Term: Hepatic steatosis System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: LLT Classification code 10041970 Term: Steatosis hepatic System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: HLT Classification code 10019669 Term: Hepatic fibrosis and cirrhosis System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: PT Classification code 10019641 Term: Hepatic cirrhosis System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0

EUCTR2018-004449-18-ESPromethera Biosciences24